FINWIRES · TerminalLIVE
FINWIRES

LTR Pharma Says Interim Phase Two Data for Erectile Dysfunction Treatment Candidate Shows Rapid Time to Peak Concentration, Shares Jump 28%

By

-- LTR Pharma (ASX:LTP) said that interim phase two pharmacokinetic and safety data for its intranasal spray for erectile dysfunction, SPONTAN, showed a rapid time to peak concentration and a consistent safety profile, according to a Friday Australian bourse filing.

The study characterized the key pharmacokinetic parameters requested by the US Food and Drug Administration (US FDA), including rapid absorption, repeat-dose behavior, and consistency across adult and geriatric populations. The data support its planned FDA 505(b)(2) regulatory pathway, subject to completion of final statistical analysis, per the filing.

SPONTAN (five milligrams) demonstrated a median Tmax of 10 minutes, compared with a median Tmax of 60 minutes for the 20mg vardenafil oral tablet. The Tmax range for SPONTAN was 10 minutes to 15 minutes,

compared with 30 minutes to 180 minutes for the oral tablet.

Pharmacokinetic profiles in subjects aged over 65 years were comparable to those in the adult cohort, with no apparent differences observed in the dataset. Intranasal administration of SPONTAN over five consecutive days did not result in drug accumulation.

No serious or severe treatment-emergent adverse events were observed, per the filing.

Its shares rose 28% in recent trading on Friday.

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Asbury Automotive Group Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $30 to $220, based on a 2027 P/E of 7.5x, a justified discount to ABG's 10-year average forward P/E of 8.6x. We lower our adjusted EPS estimates to $26.15 from $28.50 for 2026 and to $29.50 from $31.30 for 2027. ABG's same-store sales remains concerning, with revenue declining 9% Y/Y in Q1, as it continues to feel pressure from broader industry headwinds and consumer spending constraints, and is particularly notable given ABG's favorable geographic footprint concentrated in faster-growing southeastern U.S. markets. While we liked ABG's mid-2025 Herb Chambers acquisition (a top 20 private U.S. auto dealership in terms of annual revenue), the acquired assets weren't enough to offset disappointing same-store sales, driving a $260M top-line shortfall relative to consensus. We remain at Hold, seeing more compelling opportunities across the space.

$ABG
Asia

Update: Coles Group Posts Higher Group Sales Revenue in Fiscal Q3

(Updates to add stock movement in the last paragraph)Coles Group (ASX:COL) sales revenue for the fiscal third quarter was AU$10.7 billion, up from AU$10.38 billion a year earlier, according to a Friday filing with the Australian bourse.The increase was driven by a 4% growth in the supermarket segment's sales revenue to AU$9.78 billion, per the filing. Liquor sales revenue fell 3.9% to AU$781 million.The company noted that supermarket sales have stayed broadly stable in the early fourth quarter despite higher input costs, while weaker consumer sentiment in liquor since March is expected to weigh on second-half earnings through reduced cost absorption.The company's shares rose past 2% in recent Friday trade.

$ASX:COL
Asia

Marubeni's Full-Year Profit Increases 8.1%

Marubeni's (TYO:8002) profit attributable to owners of the parent rose 8.1% to 543.85 billion yen for the fiscal year ended March 31 from 503.00 billion yen a year earlier.The general trading conglomerate's earnings per share increased to 330.09 yen from 302.51 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue increased 6.1% to 8.266 trillion yen from 7.79 trillion yen in the prior year.The company declared a final dividend of 57.50 yen per share, payable from June 1.For the fiscal year ending March 31, 2027, the company expects attributable profit of 580 billion yen and basic EPS of 354.67 yen.Marubeni plans to pay interim and year-end dividends of 57.50 yen per share each for the year, which is higher than the year-ago period.

$TYO:8002